Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, Tamura Y, Chihara Y, Okabe T, Uryu K, Okuda T, Taguri M, Minami H. Hibino M, et al. Among authors: okabe t. Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20. Target Oncol. 2024. PMID: 39302602 Free PMC article.
Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Tsuya A, Okabe T, Fukuoka M, Minami H. Uryu K, et al. Among authors: okabe t. Jpn J Clin Oncol. 2024 Dec 1:hyae167. doi: 10.1093/jjco/hyae167. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39673402
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, Nakagawa K, Terashima M, Okabe T, Kaneda H, McKee MD, Carlson DM, Xiong H, Tamura T. Horinouchi H, et al. Among authors: okabe t. Cancer Chemother Pharmacol. 2014 Jul;74(1):37-43. doi: 10.1007/s00280-014-2478-9. Epub 2014 May 8. Cancer Chemother Pharmacol. 2014. PMID: 24807459 Clinical Trial.
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K. Okabe T, et al. Mol Cancer Ther. 2008 Mar;7(3):599-606. doi: 10.1158/1535-7163.MCT-07-0567. Mol Cancer Ther. 2008. PMID: 18347146
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K. Tanizaki J, et al. Among authors: okabe t. Clin Cancer Res. 2012 Nov 15;18(22):6219-26. doi: 10.1158/1078-0432.CCR-12-0392. Epub 2012 Jul 27. Clin Cancer Res. 2012. PMID: 22843788
Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB. Yoshida T, et al. Among authors: okabe t. Clin Cancer Res. 2014 Aug 1;20(15):4059-4074. doi: 10.1158/1078-0432.CCR-13-1559. Epub 2014 Jun 11. Clin Cancer Res. 2014. PMID: 24919575 Free PMC article.
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S, Haratani K, Hayashi H, Chiba Y, Tanizaki J, Kato R, Mitani S, Kawanaka Y, Kurosaki T, Hasegawa Y, Okabe T, Tanaka K, Akashi Y, Ozaki T, Nishio K, Ito A, Nakagawa K. Suzuki S, et al. Among authors: okabe t. Eur J Cancer. 2022 Jan;161:44-54. doi: 10.1016/j.ejca.2021.11.011. Epub 2021 Dec 15. Eur J Cancer. 2022. PMID: 34922263
1,298 results